Skip to main content

Table 3 Characteristics of patients in the independent test set 1

From: Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis

Sample ID

Age (years)

Sex

Bacterial isolation

Antibiotherapy before blood collection

Underlying diseases

Survival

Other sepsis (n = 11)

      

   I016* †

61

Female

Coagulase-negative staphylococci

Ceftazidime, bactrim, Sulperazole

Hematemesis

Survivor

   I017* ‡§

50

Male

Coagulase-negative staphylococci

Ceftriaxone, ceftazidime, doxycycline, cloxacillin

Acute pancreatitis, nephrotic syndrome

Survivor

   I018§¶¥

57

Male

Coagulase-negative staphylococci#

Vancomycin

T2D, CRF

Survivor

   I019¤

58

Female

Staphylococcus aureus

Cloxacillin, ceftazidime

T2D, wound

Survivor

   I020¶¥

66

Female

Coagulase-negative staphylococci#

Ceftazidime, ceftriaxone

T2D, ARF, tuberculosis

Non-survivor

   I021¶

54

Female

Enterococcus spp.

Ceftazidime, cloxacilin

T2D, abscess

Non-survivor

   I022§¶

37

Male

Coagulase-negative staphylococci#

Ceftriaxone, ceftazidime

T2D, ARF

Non-survivor

   I023¶¤

70

Female

E. coli

Doxycycline, ceftazidime

T2D

Non-survivor

   I024¶¥

56

Male

Coagulase-negative staphylococci

Meropenem, ceftazidime

T2D, RF

Survivor

   I025*

50

Male

S. pneumoniae

Ceftriaxone, meropenem

T2D

Non-survivor

   I026¶

57

Male

K. pneumoniae

Ceftriaxone, ceftazidime, bactrim

T2D

Survivor

Septicemic melioidosis (n = 13)

      

   M016¶

39

Male

B. pseudomallei

Ceftazidime, bactrim, doxycycline

T2D

Survivor

   M017¶

52

Female

B. pseudomallei

Norfloxacin, ceftazolin

T2D

Survivor

   M020¶

61

Male

B. pseudomallei

Ceftriaxone, doxycycline, ceftazidime

-

Survivor

   M021¶

56

Female

B. pseudomallei

Ceftriaxone, ceftazidime

T2D

Survivor

   M022¶

18

Male

B. pseudomallei

Ceftazidime, cactrim

T2D

Survivor

   M023¶

63

Male

B. pseudomallei

Bactrim, ceftazidime

T2D

Survivor

   M024¶

44

Male

B. pseudomallei

Meropenem

T2D, RF

Survivor

   M025¶

57

Male

B. pseudomallei

Ceftazidime

T2D

Survivor

   M026¶

48

Male

B. pseudomallei

Ceftazidime, doxycycline, bactrim

T2D

Survivor

   M027¶

44

Male

B. pseudomallei

Ceftriaxone, ceftazidime, meropenem

ARF

Survivor

   M028¶

70

Male

B. pseudomallei

Ceftazidime, levofloxacin, bactrim

T2D

Survivor

   M029¶

50

Male

B. pseudomallei

Ceftriaxone, ceftazidime

CRF

Non-survivor

   M030¶

44

Male

B. pseudomallei

Ceftazidime, ceftriazone

T2D, tuberculosis

Survivor

  1. *Hospital-acquired septicemia;†long hospitalization;‡taken immunosuppressive drugs;§dialysis; ¶community-acquired septicemia; ¥mechanical ventilation; ¤wounds. #Positive by two sets of blood cultures. ARF, acute renal failure; CRF, chronic renal failure; RF, renal failure; T2D, type 2 diabetes.